Supplementary Materials

The PDF file includes:

• Fig. S1. Establishment of a high-throughput chemical drug screen.
• Fig. S2. Drug response at 5 and 21% O₂.
• Fig. S3. Human bone marrow–derived control cells in the counter screen.
• Fig. S4. KIF11 mRNA expression and gene dependency.
• Fig. S5. Biochemical properties of ARRY-520 and AR649.
• Fig. S6. KSP abundance in neuroblastoma cells.
• Fig. S7. KSP inhibition causes neuroblastoma cell cycle arrest.
• Fig. S8. ARRY-520 causes neuroblastoma cell death.
• Fig. S9. Anti-neuroblastoma effects of KSP inhibitors SB-743921 and ispinesib.
• Fig. S10. Immunohistochemistry of tumors after AR649 treatment of mice.
• Fig. S11. Characteristics of AR649-treated LU-NB-3 PDX model.
• Fig. S12. Characteristics of ARRY-520–treated LU-NB-1 orthotopic PDX model.
• Fig. S13. Characteristics of ARRY-520–treated LU-NB-2 orthotopic PDX model.
• Fig. S14. Characteristics of low-dose ARRY-520 treatment in the LU-NB-3 PDX model.
• Table S1. KIF11 gene dependency analysis of neuroblastoma cell lines.
• Table S2. ARRY-520 sensitivity in neuroblastoma cell lines.
• Legends for data files S1 to S4
• References (53–55)

[Download PDF]

Other Supplementary Material for this manuscript includes the following:

• Data file S1 (Microsoft Excel format). Original data for figures presenting mean values.
• Data file S2 (Microsoft Excel format). Complete list of the 525 drugs (the FIMM oncology set) included in the high-throughput screen.
• Data file S3 (Microsoft Excel format). Complete data from the high-throughput drug screen.
• Data file S4 (Microsoft Excel format). Complete gene ontology list based on up-regulated genes after ARRY-520 treatment of LU-NB-2 PDX cells.